Cambridge, Mass. - March 5, 2013 -Prize4Life, a non-profit dedicated to accelerating the
discovery of treatments and a cure for ALS (Amyotrophic Lateral Sclerosis, also
known as Lou Gehrig's disease) by using powerful
incentives to attract new people and drive innovation, acknowledges and appreciates those individuals
who shared their testimony with the FDA at the public hearing on ALS held
February 25, 2013.
The first-ever public ALS FDA hearing
included presentations from many ALS organizations, scientists, clinicians,
industry representatives, ALS patients, family members, and caregivers urging
the FDA to fast track prospective drug treatment therapies. Peter Frates, a Prize4Life Board Member and
ALS patient, testified about the challenges patients and their loved-ones face battling
the disease. Additionally, Prize4life
Scientific Advisory Board Member and ALS Association Chief Scientist Dr. Lucie
Bruijn discussed the need to work collaboratively to accelerate treatments and
a cure for ALS.
is a devastating disease that attacks the nerve cells that control muscle
movement leaving patients increasingly paralyzed. On average, an ALS patient
will die within three to five years of diagnosis. Avichai Kremer, Prize4Life's CEO and Founder,
has been battling the disease since 2004.
Upon hearing the testimonies at the FDA hearing, Kremer issued this
"Prize4Life is, and will continue to
be, an active contributor in the fight to beat ALS. We will do this by working
collaboratively with fellow ALS organizations, researchers, and patients as we identify, and
partner to develop, the necessary missing resources and programs that will
transform the ALS drug development landscape. We support the efforts of those on the front-lines
battling this disease and believe that actively communicating and working in conjunction
with the FDA will lead to new treatments and a cure for ALS. We will continue to use, our prize-for-breakthrough
model, our SOD1 mouse colony, our PRO-ACT database, and our ALS Forum website to
support and accelerate the efforts of current and future ALS researchers around
the world. We applaud those who
testified at the public hearing for their help in accelerating the development
of treatments for this terrible disease, and we will continue to work to
support them with all the resources at our disposal."
day ALS researchers around the world add new pieces to the puzzle, discovering
new genes and new biological insights, and with the critical help of clinicians
and patients they are starting to fit the pieces together. Better alignment and communication between
these efforts and those of the FDA will increase the likelihood that more
effective treatments for the disease will be developed to help the thousands of
patients worldwide living with ALS.